Sep. 2018 – CRI Report

Investigation Report on China’s Gliclazide Market, 2018-2022

admin — Fri, 14 Sep 2018 01:54:15 +0000

The overweight population and the incidence of type 2 diabetes are growing in China as the economy develops, the population ages, and the lifestyle changes. The number of people with type 2 diabetes exceeded 110 million at the end of 2017, and is still rising.
Taken by mouth, Gliclazide is a second-generation sulfonylurea to treat diabetes by stimulating insulin secretion from pancreatic β-cells. It can protect pancreatic β-cells from the apoptosis caused by hyperglycemia, and prevent atherosclerosis (build-up of fatty deposits in the arteries) caused by type 2 diabetes.
Developed by French company Servier, Gliclazide (trade name: Diamicron) was first launched in France in 1972, and entered China in the 1980s. In China, at least 200,000 people with type 2 diabetes are taking Gliclazide every year.
In 1987, Tianjin Huajin Pharmaceutical Factory (now known as Tianjin Huajin Pharmaceutical Co., Ltd.) started cooperating with Servier and Tianjin Pharmaceutical Station to produce Gliclazide (Diamicron), a new drug to treat type 2 diabetes. With the support of Servier, the company has been taking the leading position on China’s Gliclazide market. Also dominating the market are Servier and Servier (Tianjin) Pharmaceutical Co., Ltd., the joint venture of Servier and Tianjin Huajin Pharmaceutical Co., Ltd.
According to CRI, the sales value of Gliclazide kept rising after the drug entered China, and exceeded CNY 200 million in 2017. It is expected that China’s Gliclazide market will continue to grow as the incidence of type 2 diabetes rises.

The post Investigation Report on China’s Gliclazide Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Irbesartan Market, 2018-2022

admin — Fri, 14 Sep 2018 01:54:15 +0000

Sartans are antihypertensive drugs with highly selective, effective and long-lasting multi-organ targeted protection. With a more specific mechanism of action, they prevent dry cough and other side effects that may be caused by angiotensin-converting enzyme inhibitors (ACEIs), and thus have replaced the ACEIs in some clinical uses. As a result, the growth of the ACEI market slows down, which leading to a steady increase in the Sartans market. Another growth driver is the new edition of List of Medicines Covered by National Basic Medical Insurance that included compound preparations.
Irbesartan was developed by Sanofi, first approved by the European Medicines Agency (EMA) on Aug. 27, 1997, and then approved by the U.S. Food and Drug Administration (FDA) on Sept. 30, 1997. The trade name of Sanofi’s Irbesartan is Aprovel. Irbesartan is mainly used to treat primary hypertension and has little effect on heart rate. Irbesartan can also protect kidneys and slow the progression of diabetic nephropathy. It can slow the progression of kidney disease for patients with both type 2 diabetic nephropathy and hypertension.
According to CRI, domestic enterprises developed the generic versions of Aprovel early. The generic drugs were approved to be sold in China in 2000. By Sept. 2018, there are 11 Irbesartan API manufacturers, and 24 manufacturers of Irbesartan tablets, capsules and dispersible tablets in China. The Irbesartan products of Sanofi and its subsidiary Sanofi (Hangzhou) Pharmaceutical Co., Ltd. have an absolute advantage in China, taking up approximately 80% market share by sales value in 2017.
There were about 330 million hypertensive patients in China at the end of 2017. One in every three adults has high blood pressure. Chinese hypertensive patients account for about one-third of the global total. The incidence of hypertension in China rose by 32.1% from 5.1% in 1959 to 37.2% in 2017.
The sales value of Irbesartan was on the rise after it entered China, exceeding CNY 300 million in 2017. It is expected that the market size will continue to grow from 2018 to 2022 with the increasing number of hypertensive patients.

Topics Covered:
– Development environment of China’s Irbesartan market
– Market demand for Irbesartan in China
– Analysis on competition on China’s Irbesartan market
– Analysis on major Irbesartan manufacturers in China
– Driving forces for China’s Irbesartan market from 2018 to 2022
– Prospect of China’s Irbesartan market from 2018 to 2022

The post Investigation Report on China’s Irbesartan Market, 2018-2022 first appeared on CRI Report.

Research Report on Thailand’s Automobile Manufacturing Industry, 2018-2022

admin — Wed, 12 Sep 2018 02:50:50 +0000

Thailand’s automobile manufacturing industry originated in the early 1970s. With its superior geographic location and government support, Thailand has become the largest automobile producer in Southeast Asia, and is called the Detroit of Asia. Automobile manufacturing has long been the pillar industry of the Thai economy. In 2017, the output value of automobile manufacturing accounted for more than 10% of Thailand’s GDP.
From 2011 to 2012, the Thai government implemented the First-Time Buyer Program to encourage automobile consumption, which led to a rapid growth in automobile production and sales. However, the automobile production dropped by 25.77% in 2014 after the program expired. Despite a steady growth, it failed to recover to the 2.53 million units in 2013. The sales declined from 2013 to 2016, and rebounded to 873,000 units till 2017. Thailand’s automotive industry is export-oriented. In the past five years, over 1 million automobiles were exported to ASEAN countries, Australia, the Middle East and Europe every year. The import volume is less. However, the import tariff on automobiles is expected to be lowered as Thailand signs more free trade agreements in recent years.
Over the years, the Thai government has introduced a series of policies to attract foreign investment. The automobile manufacturers in Thailand are mainly Japanese and US companies. The massive competitors and fierce competition make the market perfectly competitive. Compared with other Southeast Asian countries, Thailand has a developed auto parts industry and a large number of auto parts suppliers. However, it still needs to import key auto parts. There are many automobile brands in Thailand, including Toyota, Mitsubishi, Isuzu, Ford, BMW, Chevrolet, etc. which have produced a strong scale effect after years of development and production expansion. With the popularization of new energy vehicles, the Thai government also drew up a roadmap to give tax breaks and other preferential policies to new energy vehicle enterprises.
According to CRI, Thailand’s automotive industry has a good prospect. Thailand’s Eastern Economic Corridor initiative proposes to develop 10 target industries including the automotive industry in the eastern region. And the free trade agreements with Australia, China, India, New Zealand and other ASEAN countries will facilitate the development of overseas markets for Thailand’s automotive industry. The reduction of import tariffs will also provide a price advantage for automobiles. New energy vehicles will grow rapidly in Thailand with the expiration of the lock-up period of the First-Time Buyer Program, more automobiles beyond the warranty period, and the government’s efforts to develop new energy vehicles. It is expected that in the next few years, the increase in residents’ income will promote automobile consumption in Thailand. And the exemption of import tariffs on automobiles in ASEAN countries will boost Thailand’s automobile exports.
CRI expects that automobile production will continue to grow in Thailand from 2018 to 2022. It will exceed 2.4 million units in 2022, of which over 1.1 million units will be sold in Thailand and over 1.3 million units will be exported.

Topics Covered:
– Development environment of Thailand’s automobile manufacturing industry
– Analysis on supply of and demand for automobiles in Thailand
– Competition in Thailand’s automobile manufacturing industry
– Major automobile manufacturers in Thailand
– Analysis on production costs and prices of automobiles in Thailand
– Driving forces and market opportunities for Thailand’s automobile manufacturing industry from 2018 to 2022
– Prospect of Thailand’s automobile manufacturing industry from 2018 to 2022

The post Research Report on Thailand’s Automobile Manufacturing Industry, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Sildenafil Market, 2018-2022

admin — Wed, 12 Sep 2018 02:50:48 +0000

According to statistics, more than 60% of Chinese men aged 35 and above suffer from sexual dysfunction.
Sildenafil is developed by Pfizer to treat penile erectile dysfunction, pulmonary hypertension, mountain sickness, etc. Pfizer’s application for Viagra’s patent was approved by China’s State Intellectual Property Office in 1994. According to the patent law of China, the patent should be valid for 20 years till 2014. After the expiration of the patent, pharmaceutical companies can produce Sildenafil as long as they have obtained the approval. Therefore, Chinese manufacturers began to launch Sildenafil in 2014. CRI’s market investigation shows that China’s Sildenafil market is dominated by Pfizer’s Viagra, Baiyunshan’s Jinge and Yabang Aipusen’s Wanfeile. The market share of Pfizer’s Viagra, either by sales volume or by sales value, exceeded 90% in 2017. However, it will decrease as China-made counterparts are launched.
The number of erectile dysfunction patients will continue to rise in the next few years as the economy develops, the lifestyle changes, and psychological pressures increase in China. Furthermore, Sildenafil is becoming more affordable with the rise of income in China. The sales value of Sildenafil exceeded CNY 30 million in 2017, and the market will continue to grow in the next few years.

Topics Covered:
– Development environment of China’s Sildenafil market
– Sales of Sildenafil in China
– Competition pattern of China’s Sildenafil market
– Prices of Sildenafil in China’s Hospitals
– Driving forces and market opportunities for China’s Sildenafil market
– Prospect of China’s Sildenafil market

The post Investigation Report on China’s Sildenafil Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Lamivudine Market, 2018-2022

admin — Wed, 12 Sep 2018 02:50:45 +0000

At the end of 2017, there were more than 700,000 registered HIV-infected persons and AIDS patients in China. In addition, a large number of people infected with HIV and AIDS patients have not been discovered. Meanwhile, over 90 million people in China are infected with the hepatitis B virus.
Lamivudine is a major drug against the hepatitis B virus and AIDS in China. The Chinese government offers it to AIDS patients for free. Lamivudine is a nucleoside analog as well as an antiviral drug. In 1998, the FDA first approved Lamivudine as a treatment for hepatitis B. The State Food and Drug Administration (SFDA) approved the drug to be imported to China for the treatment of hepatitis B. In 1999, GlaxoSmithKline started to sell its original Lamivudine in the trade name “Heptodin” in China. More than 2 million hepatitis B patients and an unknown number of HIV-infected patients and AIDS patients are taking Heptodin in China.
By the end of 2017, more than 10 enterprises had been approved to produce Lamivudine tablets or capsules.
Lamivudine developed rapidly after it entered China. The sales volume reached CNY 307 million in 2012, declined from 2013 and fell to about CNY 159 million in 2017. The market is dominated by GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd., Wellcome Foundation, Anhui Biochem Bio-Pharmaceutical Co., Ltd. and Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd. has the largest market share. Its sales value exceeded CNY 100 million in 2017, taking up a market share close to 67%.
Considering the large number of hepatitis B and AIDS patients in China, it is expected that the market size of China’s Lamivudine market will continue to grow.

Topics Covered:
– Development environment of China’s Lamivudine market
– Size of China’s Lamivudine market
– Competition pattern of China’s Lamivudine market
– Prices of Lamivudine in China
– Driving forces and opportunities for China’s Lamivudine market
– Prospect of China’s Lamivudine market from 2018 to 2022

The post Investigation Report on China’s Lamivudine Market, 2018-2022 first appeared on CRI Report.

Research Report on China’s Synthetic Rubber Industry, 2018-2022

admin — Tue, 28 Aug 2018 05:32:09 +0000

There are various types of synthetic rubber. Rubber with special properties can be synthesized for different purposes. Therefore, the output of synthetic rubber has far exceeded natural rubber in the world. Currently, synthetic rubber is mainly produced in the U.S., China, Japan, Russia and Germany. In 2017, the global consumption of synthetic rubber exceeded 15 million tons, about 55% of which was from the Asia-Pacific region.
According to CRI, China has become the world’s largest producer, consumer and importer of synthetic rubber in recent years. With the acceleration of China’s tire industry and infrastructure, industrialized production has been achieved for eight types of synthetic rubber, i.e. styrene butadiene rubber, polybutadiene rubber, chloroprene rubber, nitrile-butadiene rubber, butyl rubber, polyisoprene rubber, ethylene propylene rubber and thermoplastic styrene butadiene rubber. In 2017, the output of synthetic rubber in China reached 5,787,000 tons, increasing by about 3.3% YOY. Synthetic rubbers, including butadiene rubber (BR), styrene butadiene rubber (SBR), nitrile-butadiene rubber (NBR) and SBS thermoplastic elastomers, vary with each other in properties, advantages and disadvantages. For example, China needs to import high-end butadiene rubber such as rare earth butadiene rubber while it has an overcapacity of styrene butadiene rubber. China still needs to import millions of tons of synthetic rubber every year to meet its domestic demand.
According to CRI, there is a structural overcapacity in China’s synthetic rubber industry, low technical barrier of general synthetic rubber, repeated development of low-end sectors, and homogeneous middle and low-end products. Since the R&D of special synthetic rubber requires huge investment and has high technical barriers, special synthetic rubber in China is mainly imported. As the Chinese government tightens the oversight for environment production, excessive capacity will be gradually eliminated, the industry will be reorganized, and the competition will be fiercer. The main raw material of synthetic rubber is butadiene. Butadiene prices fluctuate with the prices of crude oil and butadiene supply is concentrated in China. Butadiene determines the costs of synthetic rubber to a great extent. As natural rubber and synthetic rubber are substitutes for each other, the demand for synthetic rubber will be affected by natural rubber in the short term. And the price changes of natural rubber and synthetic rubber will be synchronous in some degree. Compared with synthetic rubber, natural rubber has advantages in terms of tensile strength, tear resistance and abrasion resistance. Synthetic rubber has not natural rubber’s all advantages at the application end due to limited chemical technologies. However, they satisfy some downstream demand by product diversity.
According to CRI, the main downstream industry of synthetic rubber and natural rubber is the automotive industry which contributes over 70% of the rubber consumption in China. The main demand field is automobile tires. From 2018 to 2022, China’s tire production will continue to rise and drives the development of the synthetic rubber industry with the OEM tire demand from expanding automobile production, the tire replacement demand from increasing automobile reserves, and the increase in tire exports.

Topics Covered:
– Development environment of synthetic rubber
– Supply of and demand for synthetic rubber
– Competition in China’s synthetic rubber industry
– Major synthetic rubber manufacturers in China
– Production costs and prices of synthetic rubber
– Driving forces and market opportunities for China’s synthetic rubber industry from 2018 to 2022
– Prospect of China’s synthetic rubber industry from 2018 to 2022

The post Research Report on China’s Synthetic Rubber Industry, 2018-2022 first appeared on CRI Report.

Research Report on China’s Adult Incontinence Product Industry, 2018-2022

admin — Tue, 28 Aug 2018 05:32:07 +0000

As the global population ages, the proportion of the global population aged 65 and over is gradually increasing. It increased from 7.28% in 2005 to 8.70% in 2017. The aging population has brought about a large market for adult incontinence products. Adult incontinence products are disposable health care products designed for adults with symptoms of incontinence, including adult diapers and nursing pads. At present, Japan, North America, and Europe are the major consumer markets for adult incontinence products. The penetration rate of adult incontinence products is about 80% in Japan, followed by 65% in North America and 58% in EU countries.

According to CRI, as the population of China is aging, the number of people aged 65 and over is growing in China. In 2017, China’s population in this age group reached about 150 million, ranking first in the world. The growth of the elderly population provides a huge consumer group for the adult incontinence product market. In recent years, the living standards of Chinese residents have improved. Easy and comfortable to use, adult incontinence products can reduce the burden on home-based care for the aged and improve the life quality of the elderly. More and more families and nursing homes begin to use these products. From 2013 to 2017, the market size of adult incontinence products in China soared from CNY 4.07 billion to CNY 9.28 billion.

Adult incontinence products are fast-moving consumer goods. Brand awareness and sales channels have a great impact on sales. For the enterprises in the industry, it is essential to establish trustworthy brands and huge sales networks. High-end and low-end products coexist on China’s adult incontinence product market, and the competition among international brands, domestic famous brands and local brands is becoming increasingly fierce. At present, there is no leading enterprise holding overwhelming superiority in the industry. The market concentration is very low. The broad market space will attract a large number of new entrants in the future.

According to CRI, there are many brands of adult incontinence products in China, and the prices vary greatly. The low-end market is highly competitive. In 2017, the penetration rate of adult diapers in China was about 4%, far lower than the global average of 12%. As the elderly takes up a higher proportion of China’s population, there will be greater market demand for adult incontinence products in China. At present, there is hardly any brand that specializes in the production of adult diapers in China, which means a plenty of market opportunities in the next few years.

It is expected that from 2018 to 2022, the consumption of adult incontinence products will increase sharply and reach 14.3 billion pieces in 2022. Meanwhile, the market size will reach about CNY 28 billion.

Topics Covered:
– Concept and classification of adult incontinence products
– Status of global and China’s adult incontinence product markets
– Competition in China’s adult incontinence product industry
– Major adult incontinence product manufacturers in China
– Driving forces and market opportunities for China’s adult incontinence product industry from 2018 to 2022
– Production costs and prices of adult incontinence products in china
– Prospect of China’s adult incontinence product industry from 2018 to 2022

The post Research Report on China’s Adult Incontinence Product Industry, 2018-2022 first appeared on CRI Report.